Gastricinhibitorypeptidefunction Gastric inhibiting peptide (GIP), also widely known as glucose-dependent insulinotropic polypeptide, is a crucial peptide hormone that plays a significant role in regulating insulin secretion and glucose homeostasisGIP, human 是一种由42个氨基酸组成的肽类激素，是葡萄糖依赖性胰岛素分泌的促进剂和胃酸分泌的弱抑制剂。GIP, human 作为肠K细胞释放的肠促胰岛素激素，对营养摄入作出反应 .... Produced primarily by K cells in the duodenum and jejunum of the small intestine, GIP is released in response to nutrient intake, particularly fats and carbohydrates. While its name suggests a primary role in inhibiting gastric functions, modern research highlights its more prominent involvement in the "incretin effect," a phenomenon where oral glucose stimulates insulin secretion to a greater extent than intravenous glucose. Understanding GIP's multifaceted actions is essential for comprehending digestive and metabolic processes, and its potential as a therapeutic target for conditions like diabetes and obesity.作者：K Miyawaki·2002·被引用次数：1212—Secretion ofgastric inhibitory polypeptide(GIP), a duodenal hormone, is primarily induced by absorption of ingested fat.
The most significant function of gastric inhibiting peptide is its potentiation of glucose-induced insulin secretion. When food rich in carbohydrates and fats is consumed, GIP is released into the bloodstream. It then travels to the pancreatic beta cells, where it binds to its specific receptor (GIP receptor).作者：RA Pederson·2016·被引用次数：35—GIP was shown to inhibit acid secretion in animal models, as well as stimulating gastric somatostatin secretion. However, its role in human gastric physiology ... This binding triggers a cascade of intracellular events that enhance the sensitivity of beta cells to glucose, leading to increased insulin release. This glucose-dependent action is critical because it ensures that insulin is secreted when blood glucose levels rise, helping to prevent hyperglycemia.
Beyond its direct effect on insulin, GIP also influences other pancreatic hormones. It has been shown to stimulate glucagon secretion, but this effect is generally observed only at lower glucose concentrations.Gastric Inhibitory Peptide (GIP), human As glucose levels rise, the stimulatory effect of GIP on glucagon is diminished, and in some contexts, it can even suppress glucagon release, further contributing to glucose controlGlucose-dependent Insulinotropic Polypeptide(human) (trifluoroacetate salt): An incretin hormone. Synonyms: Gastric Inhibitory Peptide, GIP. Purity: ≥95%..
While its incretin function is paramount, gastric inhibiting peptide also exhibits other physiological effects, some of which align with its historical "gastric inhibiting" moniker. GIP can indeed inhibit gastric acid secretion, though this effect is considered weaker compared to its insulinotropic action. In animal models, GIP has also been observed to stimulate gastric somatostatin secretion, a hormone that generally inhibits gastrointestinal functions. Furthermore, GIP influences lipid metabolism and adipocyte differentiation, suggesting a broader role in energy homeostasis.作者：RA Pederson·2016·被引用次数：35—GIP was shown to inhibit acid secretion in animal models, as well as stimulating gastric somatostatin secretion. However, its role in human gastric physiology ... Its secretion is primarily induced by the absorption of ingested fat, underscoring its involvement in nutrient processing beyond glucose.
The intricate role of GIP in glucose metabolism has made it a focal point for research into metabolic disorders. Dysregulation of GIP signaling or secretion has been implicated in the pathophysiology of type 2 diabetes and obesity. In individuals with type 2 diabetes, the response of pancreatic beta cells to GIP is often impaired, a phenomenon known as "GIP resistance." This reduced responsiveness contributes to inadequate insulin secretion and poorer glycemic control.2004年12月1日—The two hormones responsible for the incretin effect, glucose-dependent insulinotropic hormone (GIP) and glucagon-likepeptide-1 (GLP-1), are secreted after ...
This understanding has spurred interest in developing GIP-based therapiesGastric Inhibitory Peptide (GIP) - Springer Link. GIP receptor agonists are being investigated as potential treatments for type 2 diabetes and obesity. These drugs aim to mimic or enhance the natural effects of GIP, thereby improving insulin secretion, reducing appetite, and promoting weight lossGastric inhibitory polypeptide. The development of dual GIP and GLP-1 receptor agonists, which target both incretin hormones, represents a promising advancement in this field, offering synergistic benefits for glycemic control and weight management作者：AM Chiaravalli·2020—Gastric inhibitory polypeptide isa peptide hormone secreted by neuroendocrine cells of the proximal small intestineand plays an important physiological role ....
Gastric inhibiting peptide was first isolated in 1973, and since then, a wealth of research has elucidated its complex physiologyHuman gastric inhibitory polypeptide (GIP) is a 42 amino acid peptide belonging to the glucagon-secretin family of peptide hormones.. Ongoing studies continue to explore the nuanced interactions of GIP with other hormones and metabolic pathwaysGIP: Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion. Belongs to the glucagon family. Protein type: Secreted, .... Understanding the precise mechanisms by which GIP influences appetite, energy expenditure, and nutrient partitioning could unlock further therapeutic avenues. Additionally, research into the genetic and environmental factors that affect GIP production and signaling may provide insights into individual susceptibility to metabolic diseases. The investigation into the GIP receptor and its downstream signaling pathways remains a key area of focus for developing targeted and effective treatments.Gastric inhibitory polypeptide – Knowledge and References
Join the newsletter to receive news, updates, new products and freebies in your inbox.